To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers

NCT01751074 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Atherosclerosis

Interventions

DRUG: Rosuvastatin 10 mg
DRUG: Darapladib 160 mg

Sponsor

GlaxoSmithKline